Who founded iTeos Therapeutics?

iTeos Therapeutics was founded by Michel Detheux in 2019.

Who are iTeos Therapeutics's investors?

iTeos Therapeutics's investors include VIVES Partners, 6 Dimensions Capital, Curative Ventures, Fund+, HBM Partners, Invus, Janus Henderson Investors, MPM BioImpact and 2 more.

How much funding has iTeos Therapeutics raised?

iTeos Therapeutics has disclosed $125.4M raised across 1 round.

Where is iTeos Therapeutics headquartered?

iTeos Therapeutics is headquartered in Cambridge, US.

iTeos Therapeutics

Cambridge, US · Founded 2019 · Delaware corporation · 14 known investors

Find your way into iTeos Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the iTeos Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.

Founders & leadership

iTeos Therapeutics was founded in 2019 by Michel Detheux.

Michel Detheux Co-founder, President & CEO2019–2026Michel Detheux holds a Ph.D. in Biochemistry from the Catholic University of Louvain and has over 30 years of experience in biotechnology and life sciences. He co-founded iTeos Therapeutics and served as its President and CEO, leading the company through clinical development and securing a major partnership with GlaxoSmithKline; he previously held scientific and business development roles at Ogeda and Ludwig Cancer Research.

David HallalChairman, Board of DirectorsCEO at elevatebio

Priyanka BelawatNamed on SEC filing

CHris Buyse Member Board Of Directors2009–2020Board Member at Fund+

Jonathan SkipperNamed on SEC filing

Board

Detlev Biniszkiewicz Board of Directors2019–2023Managing Director at MPM BioImpact

Ansbert Gadicke Board directorManaging Partner at MPM BioImpact

Tim Van HauwermeirenBoard director

Investors · 14

VIVES Partnerslisted by VIVES PartnersWavre · $108K – $7.6M

How we know: VIVES Partners's portfolio page · Not right? Tell us

6 Dimensions CapitalreportedGrand Cayman

How we know: labiotech.eu · Not right? Tell us

Curative VenturesreportedDallas

How we know: labiotech.eu · Not right? Tell us

Fund+reportedLeuven · $5.5M – $16.5M

How we know: labiotech.eu · Not right? Tell us

HBM PartnersreportedZug · $5M – $50M

How we know: labiotech.eu · Not right? Tell us

InvusreportedNew York

How we know: labiotech.eu · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: labiotech.eu · Not right? Tell us

MPM BioImpactreportedBoston · $1M – $15Mvia Ansbert Gadicke · board

How we know: a partner's Signal profile · board seat on SEC Form D · labiotech.eu · Not right? Tell us

RA CapitalreportedBoston

How we know: labiotech.eu · Not right? Tell us

RTW Investments L.P.reportedNew York

How we know: labiotech.eu · Not right? Tell us

Also in the syndicate · 4

Boxer CapitalleadSFPISRIWVIVES Louvain Technology Fund

Reported raises · per SEC filings

Form D private placements

$125.4M disclosed across 1 round · 2020

▶$125.4MraisedApr 2020 · 36 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

David HallalDirector
Detlev BiniszkiewiczDirector
Michel DetheuxExecutive Officer, Director
Priyanka BelawatDirector
Ansbert GadickeDirector
Tim Van HauwermeirenDirector
CHris BuyseDirector
Jonathan SkipperDirector

Offering amount: $125.4M
Amount sold: $125.4M
First sale: Mar 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through iTeos Therapeutics went on to found or lead other companies.

Detlev BiniszkiewiczDirectorFounded MPM BioImpact +1 Ansbert GadickeDirectorFounded MPM BioImpact Jill DeSimoneIndependent Board DirectorFounded Indegene Michel DetheuxExecutive Officer, DirectorFounded Muna Therapeutics

Frequently asked questions

What does iTeos Therapeutics do?: Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Who founded iTeos Therapeutics?: iTeos Therapeutics was founded by Michel Detheux in 2019.
Who are iTeos Therapeutics's investors?: iTeos Therapeutics's investors include VIVES Partners, 6 Dimensions Capital, Curative Ventures, Fund+, HBM Partners, Invus, Janus Henderson Investors, MPM BioImpact and 2 more.
How much funding has iTeos Therapeutics raised?: iTeos Therapeutics has disclosed $125.4M raised across 1 round.
Where is iTeos Therapeutics headquartered?: iTeos Therapeutics is headquartered in Cambridge, US.